369 related articles for article (PubMed ID: 32390404)
21. Subjecting appropriate lung adenocarcinoma samples to next-generation sequencing-based molecular testing: challenges and possible solutions.
Li W; Qiu T; Ling Y; Gao S; Ying J
Mol Oncol; 2018 May; 12(5):677-689. PubMed ID: 29518290
[TBL] [Abstract][Full Text] [Related]
22. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
23. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
24. Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer.
El Achi H; Khoury JD; Loghavi S
Curr Hematol Malig Rep; 2019 Oct; 14(5):358-367. PubMed ID: 31346903
[TBL] [Abstract][Full Text] [Related]
25. The emerging clinical relevance of genomic profiling in neuroendocrine tumours.
Burak GI; Ozge S; Cem M; Gulgun B; Zeynep DY; Atil B
BMC Cancer; 2021 Mar; 21(1):234. PubMed ID: 33676450
[TBL] [Abstract][Full Text] [Related]
26. Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing.
Iwahashi N; Sakai K; Noguchi T; Yahata T; Matsukawa H; Toujima S; Nishio K; Ino K
Sci Rep; 2019 Jul; 9(1):10426. PubMed ID: 31320709
[TBL] [Abstract][Full Text] [Related]
27. Liquid Biopsy to Identify Actionable Genomic Alterations.
Ou SI; Nagasaka M; Zhu VW
Am Soc Clin Oncol Educ Book; 2018 May; 38():978-997. PubMed ID: 30231331
[TBL] [Abstract][Full Text] [Related]
28. Next-generation sequencing in liquid biopsy: cancer screening and early detection.
Chen M; Zhao H
Hum Genomics; 2019 Aug; 13(1):34. PubMed ID: 31370908
[TBL] [Abstract][Full Text] [Related]
29. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
30. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
Steeghs EMP; Kroeze LI; Tops BBJ; van Kempen LC; Ter Elst A; Kastner-van Raaij AWM; Hendriks-Cornelissen SJB; Hermsen MJW; Jansen EAM; Nederlof PM; Schuuring E; Ligtenberg MJL; Eijkelenboom A
BMC Cancer; 2020 Apr; 20(1):291. PubMed ID: 32264863
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic management of neuro-oncologic patients - potential relevance of CSF liquid biopsy.
von Baumgarten L; Kumbrink J; Jung A; Reischer A; Flach M; Liebmann S; Metzeler KH; Holch JW; Niyazi M; Thon N; Straube A; von Bergwelt-Baildon M; Heinemann V; Kirchner T; Westphalen CB
Theranostics; 2020; 10(2):856-866. PubMed ID: 31903155
[No Abstract] [Full Text] [Related]
33. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review.
Krebs MG; Malapelle U; André F; Paz-Ares L; Schuler M; Thomas DM; Vainer G; Yoshino T; Rolfo C
JAMA Oncol; 2022 Dec; 8(12):1830-1839. PubMed ID: 36264554
[TBL] [Abstract][Full Text] [Related]
34. Enrichment and Analysis of ctDNA.
Gilson P
Recent Results Cancer Res; 2020; 215():181-211. PubMed ID: 31605230
[TBL] [Abstract][Full Text] [Related]
35. The potential of liquid biopsies in gastrointestinal cancer.
Wu C; Zhang J; Li H; Xu W; Zhang X
Clin Biochem; 2020 Oct; 84():1-12. PubMed ID: 32540214
[TBL] [Abstract][Full Text] [Related]
36. Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms.
Burghel GJ; Hurst CD; Watson CM; Chambers PA; Dickinson H; Roberts P; Knowles MA
Biomed Res Int; 2015; 2015():478017. PubMed ID: 26351634
[TBL] [Abstract][Full Text] [Related]
37. [Exploratory study of circulating tumor DNA detection in early breast cancer: an analysis of 75 next-generation sequencing results].
Zhou B; Xin L; Xu L; Liu YH; Zhang MM; Jing RL; Liang XY; Cao SB
Zhonghua Wai Ke Za Zhi; 2017 Nov; 55(11):847-852. PubMed ID: 29136733
[No Abstract] [Full Text] [Related]
38. Evaluation of a Liquid Biopsy Protocol using Ultra-Deep Massive Parallel Sequencing for Detecting and Quantifying Circulation Tumor DNA in Colorectal Cancer Patients.
Nguyen HT; Tran DH; Ngo QD; Pham HT; Tran TT; Tran VU; Pham TN; Le TK; Le NT; Nguyen NM; Vo BT; Nguyen LT; Nguyen TV; Bui QTN; Nguyen HN; Luong BA; Le LGH; Do DM; Do TT; Hoang AV; Dinh KT; Phan MD; Tran LS; Giang H; Nguyen HN
Cancer Invest; 2020 Feb; 38(2):85-93. PubMed ID: 31939681
[TBL] [Abstract][Full Text] [Related]
39. High-throughput detection of clinically targetable alterations using next-generation sequencing.
Vendrell JA; Grand D; Rouquette I; Costes V; Icher S; Selves J; Larrieux M; Barbe A; Brousset P; Solassol J
Oncotarget; 2017 Jun; 8(25):40345-40358. PubMed ID: 28404952
[TBL] [Abstract][Full Text] [Related]
40. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
